FDA approves Merck/MSD’s antibiotic drug for bacterial pneumonia

Merck/MSD has won an approval from the FDA for its Gram-negative antibiotic Recarbrio, as a treatment for hospital-acquired and ventilator-associated bacterial pneumonia. Recarbrio is a combination treatment comprised of imipenem, a carbapenem antibacterial, cilastatin, a renal dehydropeptidase inhibitor, and relebactam, a beta-lactamase inhibitor. Imipenem works to kill the bacteria associated with the infection while the other

Continue Reading

MSD’s Bladder cancer treatment, Keytruda approved in EU following superior survival rates

Merck Sharp & Dohme’s Keytruda has received approval in Europe for metastatic urothelial carcinoma allowing it to catch up with its immunotherapy rivals. Although, while BMS’ Opdivo and Roche’s Tecentriq beat MSD to approval in Europe earlier this year, Keytruda is the first treatment to show superior overall survival when compared to using chemotherapy in

Continue Reading

BioCity Scotland Secures Former MSD Research Plant

A new joint partnership between BioCity Nottingham and Scotland’s Roslin BioCentre, known as BioCity Scotland, announced yesterday has given Scotland’s life sciences sector a major boost, taking away some of the disappointment of MSD’s decision to close down their pharmaceutical research facility at Newhouse, Scotland. Under the proposal of the joint partnership, the facility at

Continue Reading